- Zydus Lifesciences reported a net income of 10.2 billion rupees for the third quarter, which is a 29% increase compared to the previous year and above the estimated 8.93 billion rupees.
- The company’s revenue for the quarter was 52.7 billion rupees, marking a 17% year-over-year growth and surpassing the estimated 52.04 billion rupees.
- Total costs for the period amounted to 41.4 billion rupees, up by 14% year-over-year, and exceeding the estimated 37.77 billion rupees.
- Other income stood at 575 million rupees, reflecting a significant increase of 53% from the previous year.
- Market analysts’ recommendations include 17 buys, 10 holds, and 6 sells for Zydus Lifesciences.
Zydus Lifesciences Ltd on Smartkarma
Investment analysts on Smartkarma are closely covering Zydus Lifesciences Ltd, with analyst Tina Banerjee recently publishing a bullish report titled “Zydus Lifesciences (ZYDUSLIF IN): Q1FY25 PAT Jumps 31%; Increasing Focus on US To Augur Well“. The report highlights Zydus Lifesciences’ stellar Q1FY25 performance, driven by record operating profit and margin stemming from the US and India markets. The company is reaffirming its high teens revenue growth outlook for FY25, showcasing sustained growth momentum and enhanced profitability across all business segments. Notable successes include the execution of a differentiated pipeline in the U.S. and strong performance in the India segment, with Zydus maintaining its revenue growth guidance despite already achieving 21% YoY revenue growth in Q1FY25.
A look at Zydus Lifesciences Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Zydus Lifesciences Ltd demonstrates a promising long-term outlook. With solid scores in Growth, Resilience, and Momentum, the company appears positioned for sustained success in the healthcare sector. Zydus Lifesciences Ltd is recognized for its consistent performance and ability to adapt to market changes, reflecting positively on its future prospects.
Zydus Lifesciences Ltd, a subsidiary of Cadila Healthcare Ltd, is a key player in the healthcare industry, offering a diverse range of healthcare solutions. From pharmaceuticals to healthcare products for animals, Zydus Lifesciences Ltd caters to a wide consumer base. With a balanced combination of Value, Dividend, Growth, Resilience, and Momentum scores, the company demonstrates a holistic approach towards maintaining its competitiveness and driving long-term growth.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
